Mary Halbrooks
Primary Care · Hartselle, ALNPI 1780151514
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.
Across 221 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$732
- Boehringer Ingelheim$490
- AstraZeneca$487
- Lilly USA, LLC$392
- AbbVie$253
- Takeda Pharmaceuticals U.S.A., Inc.$202
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,770100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,770 in reported general payments places this provider in the 85th percentile of 159 primary care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 39 | $52,278 |
| EliquisApixaban | 24 | $24,834 |
| OzempicSemaglutide | 19 | $22,350 |
| FarxigaDapagliflozin Propanediol | 18 | $18,036 |
| RexultiBrexpiprazole | 11 | $16,673 |
| LinzessLinaclotide | 24 | $16,003 |
| XareltoRivaroxaban | 19 | $14,061 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $13,230 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $9,380 |
| JanuviaSitagliptin Phosphate | 13 | $8,287 |
| TrintellixVortioxetine Hydrobromide | 14 | $7,436 |
| Levothyroxine Sodium | 147 | $2,118 |
| Valsartan | 18 | $1,322 |
| Cefdinir | 64 | $1,126 |
| Pravastatin Sodium | 74 | $921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $392 | $52,27839 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $487 | $31,26536 claims |
| PfizerEliquis | $31 | $24,83424 claims |
| Novo NordiskOzempic | $732 | $22,35019 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $28 | $16,67311 claims |
| AbbVieLinzess | $253 | $16,00324 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $49 | $9,38012 claims |
| MerckJanuvia | $14 | $8,28713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $202 | $7,43614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 primary care providers in Alabama.
Other primary care in Hartselle
- Keith MatthewsOpelika$20K
- Troy HendersonFultondale$18K
- April TateDothan$16K
- Brandy McGrawMobile$14K
- Cleo ValdezHuntsville$14K
- Larissa RobinsonJasper$11K
- Jamie GhrigsbyMoulton$9K
- Josh WarrenBirmingham$9K
- Amber NelsonHoover$9K
- Valerie ZiemanFoley$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.